USPTO serial 74701900
SANKYO
Reviewed by CopyMark Law Group
Reg. 2096384Status 710
- Filing date
- Status date
- Registration date
- Sep 16, 1997
- Examiner
- LEVINE, HOWARD B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with SANKYO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chuo-ku, Tokyo, JP
Chuo-ku, Tokyo, JP
Chuo-ku, Tokyo, JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David Toren
KATRIN LEWERTOFF SIDLEY AUSTIN LLP787 7TH AVENEW YORK, NY 10019UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical food preservatives; plasticizers, high polymer stabilizers for plastics and paints; antioxidants for use in the manufacture of drinks, cakes, flavoring agents, dairy products and fish paste products, germination controllers, namely, gibberellins for grapes, oranges, and cedars for clothing tests for domestic and/or agricultural use; hormone-based preparations for application to domestic and/or agricultural plants; tetrodotoxins for scientific research use | SECTION 8 - CANCELLED | — |
| 005 | in vitro diagnostic reagents for medical use, in vitro extracorporeal diagnostic reagents for medical use, in vitro X-ray contrast agents for medical use, in vitro diagnostic media; central nervous system depressants; preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactics for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids; hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis; estrogen and progesterone used as combined oral contra-ceptives; urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago, stiffness and for the treatment of the shoulder; preparations used to treat hair disorders; vitamin preparations, food enriching agents for treating vitamin deficiencies, anticoagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelminitics for treatment against threadworm and for the treatment of toxoplasmosis; excipients, namely, tablet coating polymers soluble in the gastric tract; beta carotene used as a coloring agent for pharmaceutical preparations; naturally occurring drugs and charred drugs and moxa for the treatment of peptic ulcers; veterinary drugs for the treatment of distemper in dogs; veterinary drugs for the treatment of distomatosis in dogs; veterinary drugs for the treatment of coccidium in chickens; veterinary drugs for the treatment of dysentery in pigs; insecticides, rodenticides and herbicides for domestic and/or agricultural use; antiseptics; drugs for arterio-sclerosis; oncostatic drugs for the treatment of cancer; multienzyme digestants; antifungal antibiotics for the treatment of trichomoniasis and dermatophytosis; antiparkinsonism agents, minor tranquilizing agents, and antianxiety agents | SECTION 8 - CANCELLED | — |
| 030 | food additives for non-nutritional purposes for use as a flavoring, ingredient or filler | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SANKYO COMPANY LIMITED
- Other trademarks owned by SANKYO COMPANY LIMITED
- Other trademarks owned by SANKYO COMPANY LIMITED
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 030
- Similar marks named SANKYO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 13, 2006 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 19, 2004 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Feb 26, 2003 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 16, 1997 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 24, 1997 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 23, 1997 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 6, 1997 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 25, 1997 | CNEA | EXAMINER'S AMENDMENT MAILED | — |
| Oct 24, 1996 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 5, 1996 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 4, 1996 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 28, 1995 | DOCK | ASSIGNED TO EXAMINER | — |